MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
26.79
+0.50
+1.90%
After Hours: 27.06 +0.27 +1.02% 17:43 01/02 EST
OPEN
26.28
PREV CLOSE
26.29
HIGH
27.66
LOW
25.99
VOLUME
793.77K
TURNOVER
--
52 WEEK HIGH
27.66
52 WEEK LOW
6.42
MARKET CAP
1.43B
P/E (TTM)
-14.2530
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TYRA last week (1222-1226)?
Weekly Report · 12/29/2025 10:05
Tyra Biosciences (TYRA): Assessing Valuation After New Leadership Hires and Biotechnology Index Inclusion
Simply Wall St · 12/26/2025 01:21
Weekly Report: what happened at TYRA last week (1215-1219)?
Weekly Report · 12/22/2025 10:05
Tyra Biosciences (TYRA) Is Up 12.7% After Wedbush Highlights Pipeline Momentum And Leadership Refresh - What's Changed
Simply Wall St · 12/20/2025 13:15
Tyra Biosciences Director Robert J. More Reports Sale of Common Shares
Reuters · 12/20/2025 02:00
Tyra Biosciences Chief Discovery Officer Daniel Bensen Reports Sale of Common Shares
Reuters · 12/16/2025 21:30
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 12/16/2025 12:58
Tyra Biosciences Price Target Raised to $37.00/Share From $30.00 by Wedbush
Dow Jones · 12/16/2025 12:46
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.